Slingshot members are tracking this event:

International Phase 3 Study Results of RLX030 (seralaxin) for Acute Heart Failure Due 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details Update on March 2 2017: This study has been completed.
Additional Relevant Details A second ongoing Phase III study follows a request from Canadian regulators for more evidence of the therapy’s efficacy, with results expected by 2017.  Regulatory applications were filed based on Phase II and III studies suggesting RLX030 helped patients with acute heart failure live longer.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 02, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Data, Rlx030, Seralaxin, Acute Heart Failure